AI matched optical heart maps in six porcine hearts—but patient benefit is untested
A Japanese system reconstructed complex atrial conduction from catheter signals, then showed different patterns in 12 patients. It has not yet guided treatment or improved outcomes.
The short version
- What happened
- The convolutional network was trained on 13,824 simulated samples, then compared with optical mapping in six ex vivo porcine hearts.
- Who it affects
- More informative mapping might eventually help personalise atrial-fibrillation ablation, but this study does not show that patients receive safer procedures or fewer recurrences.
- What remains unproven
- Only six ex vivo porcine hearts and 12 retrospective patient records
Keep in mind
Only six ex vivo porcine hearts and 12 retrospective patient records
No clinical optical-mapping reference or prospective treatment comparison
No recurrence, safety or patient-outcome endpoint
Equity, directorship, patent and proprietary-method interests
Source analysis · 1 linked source. Primary analysed source date: 25 October 2026.
Keep following the evidence
Join The Impact Brief founding list for selected AI reports, their effect on people and the evidence limits. Read a sample first.
Read the full report · 3 min The evidence, methods, implications and limitations
The model reconstructed conduction without marking local activation times
Researchers trained Deep-learning-based Electrode Action Potential Mapping, or DEAP Mapping, on 13,824 simulated examples from a fibrotic human-atrial model. The aim was to reconstruct membrane-potential patterns directly from unipolar intracardiac electrograms, avoiding the local activation-time annotations that become unreliable during complex conduction.
In six isolated porcine hearts, optical fluorescence mapping supplied the comparator. Phase-variance maps from DEAP Mapping reached mean structural similarity of 0.87 with a 0.07 standard deviation, compared with 0.36 ± 0.14 for conventional activation maps. That supports technical reconstruction under controlled ex vivo conditions.[1]
Twelve patient records show feasibility, not a treatment advantage
The team then applied the system retrospectively to catheter recordings from 12 people with non-paroxysmal atrial fibrillation. It produced spatially continuous patterns of conduction heterogeneity that partly differed from existing maps and varied between patients. There was no patient-level optical reference, however, and the study did not use those maps to choose ablation sites.
The next step is a prospective, multi-centre study comparing predefined targeting strategies and measuring recurrence, procedure time and complications. Two authors hold equity in and direct OpMap Inc.; four authors are named inventors, and one signal-processing step is proprietary. Those interests do not invalidate the result, but they raise the value of independent replication.[1]
The distinction that matters
The validation ladder
The evidence moves from simulation to controlled tissue and then to a small retrospective clinical series.
Simulation
Train on 13,824 modelled samples
Learns conduction patterns
Porcine hearts
Compare with optical mapping in six hearts
SSIM 0.87 ± 0.07
Patients
Apply retrospectively in 12 people
Feasibility only
Watch the background, then check the evidence
Illustrative photo · not a video frame
The Royal Society · 44 min 28 sec · Background explainer
Is this the AI future we want? | The Royal Society
YouTube loads only when you choose; playback starts when you press play.
A Royal Society discussion with Madhumita Murgia and biomedical engineer Alison Noble on AI’s potential in healthcare, science and culture, recorded at the 30 June 2026 event.
Evidence check: A discussion of opportunities and risks, including future possibilities. It is not evidence that every application described is available or clinically proven.
Published 2026-07-01. Source checked 14 October 2026. Check captions on the publisher’s video page.
Check the healthcare evidencePhoto: Daniel Sone / National Cancer Institute / Unsplash · Licence
Continue the story
Read next
A second perspective on AI in health & life sciences, with its own sources and qualifications.
Medical AI got better at arithmetic—and still missed clinical meaning
A tool-based system answered 86.73% of 1,100 benchmark cases correctly, but its remaining errors centred on extracting symptoms, timing and implied history. No patient care was tested.
Read the next reportExplore the full source and evidence record
What this means for people
- More informative mapping might eventually help personalise atrial-fibrillation ablation, but this study does not show that patients receive safer procedures or fewer recurrences.
Global context
All experimental and clinical work was conducted in Japan. Catheter systems, signal processing and ablation practice differ across centres and countries.
What the evidence does not yet show
- Only six ex vivo porcine hearts and 12 retrospective patient records
- No clinical optical-mapping reference or prospective treatment comparison
- No recurrence, safety or patient-outcome endpoint
- Equity, directorship, patent and proprietary-method interests
What to watch next
- Independent multi-centre replication
- Prospective ablation-targeting trial
- Recurrence and safety outcomes
- Transparent evaluation of the proprietary processing step
Living evidence record
Impact record IAI-0KQACOJ
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
25 October 2026
Source trail
1 direct source across 1 source type.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Single-source reporting disclosure
This record analyses one direct source. It can establish what Scientific Reports published or reported, but it is not independent corroboration of every performance claim or predicted outcome. The confidence label will change only when broader evidence is added.
Evidence trail
Sources used for this report
Links checked 25 October 2026
Research question, topics and regions
Whether deep learning can reconstruct membrane-potential maps from annotation-free intracardiac electrograms and reveal atrial-fibrillation substrate patterns
Topics: Atrial fibrillation · Catheter ablation · Cardiac mapping · Clinical AI validation
Regions: Japan
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.